Tracon's carotuximab fails Phase II for RCC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) said carotuximab (TRC105) plus Inlyta axitinib missed the

Read the full 128 word article

How to gain access

Continue reading with a
two-week free trial.